Letter from the CEO

Entering global development phase

2025 marked a pivotal year for Cereno Scientific. We moved from encouraging Phase IIa data with CS1 to establishing a regulatorily aligned and operationally ready global Phase IIb program. At the same time, our second HDACi asset, CS014, delivered positive Phase I results and is progressing toward Phase II, reinforcing the depth and scalability of our HDAC inhibitor platform. As we enter 2026, our priority is clear: initiate the global Phase IIb trial with CS1, maintain close regulatory interaction and execute the trial with operational excellence.

CS1 — ready for global Phase IIb

During the year, the development of CS1 for pulmonary arterial hypertension (PAH) has reached central milestones. Following positive Phase IIa data and a successful Type C meeting with the FDA, we received the Agency's endorsement for the planned Phase IIb study and partnered with a leading global CRO to support its execution. In August, CS1 was granted FDA Fast Track designation, enabling closer regulatory interaction and the potential to accelerate development timelines. In the fourth quarter, we obtained regulatory clearance from the FDA allowing us to initiate the Phase IIb trial.

Overall, this means that the regulatory and operative risk ahead of the Phase IIb trial has been significantly reduced. The trial is designed on the back of positive Phase IIa data, to further evaluate safety, tolerability and efficacy, including the potential to impact underlying disease mechanisms, as well as determining optimal dose for Phase III. It is the first PAH Phase IIb trial with a design that includes a longer exploratory phase to evaluate signs of disease modification. The trial is planned to start during the second quarter of 2026.

Expanded Access Program — operational milestone and upcoming insights

The Expanded Access Program (EAP) for CS1, which allowed eligible patients who completed the Phase IIa trial to continue treatment under a formal protocol, reached an important operational milestone when the final patient completed their last visit in the 12-month active treatment period.

Initial learnings from the EAP are expected to be available in the first quarter of 2026, with further analyses planned during the second quarter of 2026. These insights are intended to complement the Phase IIa data with longer-term information on safety, tolerability and exploratory imaging sub-studies, which will contribute to the overall understanding of CS1's potential and its value proposition.

CS014 — next-generation HDAC inhibitor with sharpened development focus

During the year, positive topline data from the Phase I trial of CS014 was reported. The trial demonstrated a favorable safety and tolerability profile at achieved exposure levels predicted to impact disease-driving processes such as fibrosis and vascular remodeling. The Phase I results, together with previous non-clinical studies, support CS014 as a promising candidate for the treatment of cardiovascular and pulmonary diseases where vascular remodeling, fibrosis, and thrombosis play key roles.

CS014 received external scientific validation through the publication of its first peer-reviewed manuscript in the Journal of Thrombosis and Haemostasis (JTH), which is a key foundational element for scientific credibility as the asset advances in development. Presentations of data at international scientific conferences, including Pharmacology 2025, and most recently at PVRI 2026 in January, has further contributed to increased awareness and visibility of our pioneering epigenetic approach within the scientific community.

At the beginning of 2026, we announced that CS014 will be developed for pulmonary hypertension associated with interstitial lung disease (PH-ILD) — a severe condition with high unmet need. This focus is intended to enhance the clinical relevance of the upcoming Phase II study and accelerate the pathway to relevant outcomes by targeting a patient population characterized by both fibrotic lung disease and pulmonary vascular involvement. A Phase II trial is planned to start early 2027.

CS014 represents the next generation within our epigenetic HDAC inhibitor platform. The platform addresses the central biological processes including fibrosis, inflammation, vascular remodeling and thrombosis – which are fundamental drivers across a broad range of cardiopulmonary diseases.

The clinical progress with CS014 not only advances the program but also reinforces the long-term potential of our HDAC inhibitor platform.

Scientific & Strategic positioning — ahead of the curve

In 2025, we strengthened our scientific and strategic profile through participation in international partnering and investor events, scientific presentations and peer-reviewed publications. Our Capital Markets Day in Stockholm, held on February 5, brought together clinical experts, a patient representative and investors and articulated the company's long-term direction: to lead a paradigm shift in PAH from symptomatic treatment to disease modification.

In a market where several major pharmaceutical companies are facing extensive patent expirations, demand is increasing for differentiated clinical-stage projects, particularly in orphan drug areas with regulatory support. Projects that combine clinical maturity, biological differentiation, and commercial rationale are often prioritized in partnering discussions. It is in this context that we position CS1, CS014 and our epigenetic HDACi platform.

Financial position & Capital structure

During the year, the remaining convertible loans of SEK 75 million from a financing agreement in November 2024 were converted into shares, further strengthening the balance sheet.

In November 2025, the company secured a financing package of approximately SEK 665 million upon full exercise of warrants and convertibles providing financial runway to Q4 2027. The financing comprised a directed share issue of SEK 100 million, completed at a premium to the market price, and a loan financing facility of up to SEK 350 million. Major shareholders and new investors participated in the transaction, demonstrating confidence in the Company's long-term strategy.

The company's financial position supports the execution of planned near-term development activities, including the global Phase IIb program for CS1 and continued advancement of CS014. As Cereno Scientific progresses into the next stage of clinical development, the company continuously evaluates its capital strategy to support ongoing operations and upcoming value-inflection milestones.

Looking forward — catalysts & market context

As we enter 2026, our priorities are clear:

- Initiate the global Phase IIb study with CS1
- Share initial learnings from the CS1 EAP in Q1–Q2 2026
- Drive forward the CS014 Phase II development in PH-ILD
- Continue to engage in business development (BD) activities toward partnering and deals to support our growth

The initiation of the Phase IIb program represents the most important operational milestone in the company's history to date and a pivotal step in the clinical development of our disease-modifying lead asset at scale.

Beyond clinical development, we believe the market environment remains favorable for differentiated rare disease projects. Capital allocation in the sector is increasingly directed toward programs with clear scientific differentiation, regulatory advantages and meaningful patient impact. This dynamic, combined with broader industry patent expirations and strategic portfolio needs, supports our positioning and ongoing partnering discussions.

As this report is published, Rare Disease Day on February 28 approaches. It is a reminder of why we pursue our work: for patients living with rare and serious diseases where disruptive therapies are needed with significant impact on disease progression, quality of life and prognosis.

I extend my sincere thanks to our shareholders, partners and patients for their continued trust and support. We enter 2026 with determination, strategic focus and confidence in the path ahead.

February 2026

Sten R. Sörensen
Chief Executive Officer